Artiva Biotherapeutics (ARTV) vs Inhibikase Therapeutics (IKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 20.8% versus a loss of 11.4%. Artiva Biotherapeutics is the larger company by market cap ($186.9 million vs $185.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | IKT |
|---|---|---|
| Share price | $3.78 | $1.32 |
| Market cap | $186.85M | $185.16M |
| 1-day change | -1.31% | +1.54% |
| YTD return | -11.89% | -35.61% |
| 1-year return | +20.77% | -11.41% |
| 5-year return | — | -89.32% |
| EPS (TTM) | $-2.85 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-83.86M | $-48.26M |
| 52-week high | $14.53 | $2.61 |
| 52-week low | $2.96 | $1.28 |
| Distance from 52-week high | -73.98% | -49.43% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +448.94% | +320.45% |
| Average volume | 792.26K | 584.27K |
| Shares outstanding | 49.43M | 140.27M |
| Employees | 134 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed IKT by 32.2 percentage points over the past year.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
ARTV vs IKT FAQ
Which is bigger, Artiva Biotherapeutics or Inhibikase Therapeutics?
Artiva Biotherapeutics (ARTV) is larger, with a market capitalization of $186.85M compared with $185.16M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, ARTV or IKT?
ARTV returned +20.77% over the past 12 months, compared with -11.41% for IKT (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Inhibikase Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.